1. Introduction {#sec1}
===============

Obesity is characterized by abnormal or excessive fat accumulation that is the result of a chronic imbalance between energy intake and energy expenditure \[[@B1], [@B2]\]. It poses a substantial health risk, as obesity is linked to several common diseases, such as type 2 diabetes, cardiovascular disease, stroke, arthritis, and several types of cancer \[[@B3]\]. Obesity can be highly heritable, and some specific genes related to obesity have been identified \[[@B4]\]. However, over the past decade, the prevalence of obesity in the world has dramatically increased across all age groups, especially in developed countries \[[@B5]\], so that genetic factors alone cannot explain the obesity epidemic. It is widely agreed that obesity is a complex multifactorial disease involving genetic, environmental, and lifestyle factors \[[@B6]\] and it is necessary to investigate the mode of action of each contributing factor in order to reduce the associated health risks.

Metabolomics is a newly emerging bioanalytical technique similar in scope to genomics and proteomics that uses analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy or mass spectrometry (MS) to characterize and quantify all small molecules in biological samples to achieve comprehensive global monitoring of metabolites and their fluctuations in response to various stimuli \[[@B7], [@B8]\]. Therefore, metabolomic data can provide the information on what is actually happening in a biological system, serving as the crucial link between phenotype and genetics. To date, metabolomics has demonstrated enormous potential in furthering the understanding of disease processes \[[@B9]\], toxicological mechanisms \[[@B7], [@B10]\], biomarker discovery \[[@B11]\], and gut microbiome-host variations \[[@B12], [@B13]\]. Obesity is a disorder of the whole body and obviously involves metabolic changes, but the actual alterations in metabolism during obesity and any dysfunction associated with obesity at the level of individual organs or cellular organelles are not yet clearly understood \[[@B2]\]. As metabolomics can readily detect subtle changes in the metabolic network, it is uniquely poised to increase our understanding of obesity and obesity-related diseases.

Animal models have provided a fundamental contribution to the investigation of the onset and progression of complex multifactorial diseases such as obesity \[[@B14]\]. The greatest advantage of animal models is that they allow strict control of factors such as diet, environmental conditions, or genetic background. Thus, animal models have been widely used in metabolomics for exploring the metabolic changes and potential biochemical mechanisms of obesity development.

The general process of a metabolomics study includes appropriate design and sampling of experimental study cohorts, selection of analytical technique (NMR spectroscopy and/or MS), data preprocessing and statistical analysis, identification of candidate biomarkers, and elucidation of their biological relationship. How to obtain metabolic profiles from biological fluids and how to analyse metabolomic data will not be discussed in detail in this paper as these topics have been thoroughly reviewed elsewhere \[[@B7], [@B15]--[@B17]\]. We will focus here on individual significant metabolites and metabolic pathways related to obesity which have been identified by metabolomics.

2. Investigation of Obesity-Associated Metabolites by Metabolomics {#sec2}
==================================================================

Recently, many obesity-related metabolites have been identified by metabolomics and demonstrated to be disturbed significantly in both animal models and humans. [Table 1](#tab1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"} show a summary of these metabolites and their relationships in metabolic pathways, respectively. We will discuss several of these metabolites in more detail below.

2.1. Metabolites Related to Glucose Metabolism and Tricarboxylic Acid (TCA) Cycle {#sec2.1}
---------------------------------------------------------------------------------

*Glucose* is a key source of energy for most organisms. It is catabolised via glycolysis to pyruvate, which under aerobic conditions is converted into acetyl coenzyme A (AcCoA), the entry point into the TCA cycle. Under anaerobic conditions, pyruvate is instead converted to lactate by the enzyme lactate dehydrogenase. It was found that the concentration of *lactate* in urine, blood, or liver tissue is elevated in obese mice induced by high-fat diet (HFD), or in obese Zucker rats lacking the leptin receptor, compared to their lean controls ([Table 1](#tab1){ref-type="table"}) \[[@B18]--[@B22]\]. One study found lower lactate levels in the urine of obese Zucker rats, but this decrease was only small compared to other metabolite changes and could have been caused by small cohort sizes \[[@B23]\]. The findings of generally higher lactate levels in obese Zucker rats are consistent with higher blood lactate levels in obese humans measured by conventional methods \[[@B24]\]. It was presumed that the elevation of lactate in obese animals was the result of upregulated anaerobic glycolysis when compared to lean controls \[[@B18], [@B19]\]. The blood concentration of lactate is largely determined by the balance of the rate of lactate production (which mainly takes place in skeletal muscle, the erythrocytes, brain \[[@B25]\], and adipose tissue \[[@B26]\]) relative to the rate of its removal by other tissues or by urinary excretion. Importantly, subcutaneous fat was demonstrated to be a significant source of lactate; therefore, obese subjects have a greater apparent lactate release due to their larger adipose mass, and a higher plasma lactate than lean individuals \[[@B26]\]. Lactate is also the major precursor for gluconeogenesis in the body, and the rise in plasma lactate in obesity may be an indicator of perturbation of hepatic glucose production and hepatic lipid synthesis. Thus, lactate is an important obesity-related metabolite identified by metabolomics.

Under aerobic conditions, *pyruvate* enters the TCA cycle via AcCoA to produce energy via formation of *citrate*, and other TCA cycle metabolites. It was reported that inhibition of citrate metabolism by fluoroacetate, a chemical inhibitor, reduced body fat in mice \[[@B27]\]. Next to glucose catabolism, AcCoA and consequently citrate are in animals also generated by fatty acid oxidation. The concentration of citrate in plasma is regulated by insulin, glucose levels, fatty acid utilization, cholesterol synthesis, liver clearance and renal excretion \[[@B28]\]. Blood citrate was found to be increased in alloxan-induced diabetic rats \[[@B29]\], and lowered upon insulin administration in experimental animal models \[[@B30]\] and children \[[@B31]\]. Similarly, higher serum concentrations of citrate when compared to their controls were detected by NMR \[[@B28]\] or gas chromatography-MS (GC-MS) \[[@B32]\] based metabolomics in HFD-fed obese animals with insulin resistance. Conversely, lower urinary citrate excretion was reported to be associated with a higher level of insulin resistance in humans \[[@B33]\], and depletion of urinary citrate excretion was reported in obese animals with insulin resistance \[[@B32]\], while the opposite was seen in obese animals without insulin resistance \[[@B20]\]. Depletion of urinary citrate excretion was also found in obese animals, with truncations in the intracellular domain of the growth hormone receptor (GHR) \[[@B34], [@B35]\]. Urinary citrate excretion is influenced by the acid-base status of the body \[[@B36]\], with alkalosis inducing an increase in urinary citrate excretion, and acidosis having the opposite action. Obesity, especially in conjunction with insulin resistance, can increase metabolic acidosis and thus result in a reduction of urinary citrate excretion \[[@B37]\]. Thus, citrate can be used as a marker related to insulin or glucose levels in metabolic studies.

2.2. Metabolites Related to Lipid Metabolism {#sec2.2}
--------------------------------------------

Lipids are an important source and store of energy for metabolism. Blood lipids, derived from food intake or adipose tissue and liver, are mainly fatty acid derivatives and cholesterol. High concentrations of fatty acids or cholesterol in blood have been used as an indicator of disease risk, as their alteration is related to some cardiovascular diseases, such as coronary heart disease, diabetes \[[@B38], [@B39]\], and hypertension \[[@B40]\]. In liver and muscle, *free fatty acids*(FFAs) are catabolised in the mitochondria to produce energy through  *β*-oxidation and the TCA cycle, whereas excess lipids are stored in adipose tissue and elsewhere as triglycerides \[[@B41]\]. Obesity, characterized by fat deposits in tissue, is generally associated with elevated levels of plasma FFAs \[[@B42]\]. In agreement with this, elevation of FFAs in serum and liver of obese animals has been observed by metabolomic analysis ([Table 1](#tab1){ref-type="table"}). Furthermore, the serum FFA composition, especially the proportion of saturated fatty acids (SFAs), has been found to be positively associated with the development of obesity and diabetes \[[@B43]\]. In contrast, lower levels of essential fatty acids such as linoleic acid were found in circulating lipids of obese patients \[[@B44]\].

Compared to conventional targeted analysis of FFAs, metabolomics can provide a more unbiased relationship of FFAs to other small molecules, which may help to understand obesity. For example, based on ultraperformance liquid chromatography quadrupole time-of-flight (UPLC Q-TOF) MS and GC-MS, higher levels of stearic acid, total SFAs and palmitoleic acid and lower linoleic acid levels, as well as the variation of amino acids and carnitine in plasma, were detected in overweight/obese men \[[@B45]\].

*Carnitine* is a key metabolite related to obesity, due to its involvement in fatty acid metabolism. It is well documented that provision of FFAs can promote fatty acid oxidation \[[@B46]\]. However, fatty acids can only produce energy via *β*-oxidation after esterification and transport into the mitochondrion with the help of carnitine \[[@B47]\]. Thus, higher plasma FFAs in obesity may require more carnitine for efficient *β*-oxidation. Consequently, the amount of carnitine in cells is an important factor regulating the process of *β*-oxidation. Indeed, it has been reported that supplementation of carnitine can diminish the risk of obesity caused by a HFD in C57BL/6J mice \[[@B48]\], and carnitine is popularly used as a weight loss product \[[@B49]\]. Consistent with this picture, depletion of carnitine levels was observed in liver tissue of obese mice \[[@B41]\] or blood samples of obese humans \[[@B45]\]. The decreased carnitine levels in obesity could be insufficient for *β*-oxidation to compensate the elevation of FFAs, and as a result, contribute to fat accumulation in adipose tissue.

*Taurine* is an important metabolite in bile acid metabolism and has many important biological roles such as conjugation of cholesterol and bile acids, antioxidation, osmoregulation, and modulation of calcium signaling \[[@B50]\]. In a rat model of type 2 diabetes, a taurine-supplemented diet tended to decrease total fat weight in the abdominal cavity and improved insulin sensitivity \[[@B51]\]. Similarly, Zhang et al. reported that taurine supplementation significantly decreased serum lipids and body weight in obese individuals \[[@B52]\]. Based on ^1^H-NMR spectroscopy and microarray techniques, significant depletion of hepatic and urinary taurine, as well as lower expression of cysteine sulfinic acid dehydrogenase (*Csad*) in GHR mutant obese mice, was observed when compared with wild-type mice in our previous work \[[@B34]\]. The findings indicated that lower urinary taurine levels in the mutant mice can reflect lower hepatic taurine biosynthesis in GHR mutant mice. Lower urinary excretion of taurine was also reported in obese Zucker rats \[[@B21], [@B53]\] ([Table 1](#tab1){ref-type="table"}). These observations indicate that a decreased production of taurine in liver due to inhibition of taurine biosynthetic enzymes is closely related to obesity.

Interestingly, we found that the hepatic taurine level in liver was increased significantly when wild-type mice were fed an HFD \[[@B34]\]. Recently, Rubio-Aliaga et al. \[[@B54]\] confirmed that not only elevation of hepatic taurine, but also depletion of the expression of two key enzymes involved in taurine biosynthesis, cysteine dioxygenase (CDO) and Csad, was observed in HFD-induced obesity mice. Similar results of elevated taurine levels in liver extracts but decreased urinary taurine were also found in another study on HFD-fed obese mice \[[@B55]\].

*In vivo*, taurine in liver is supplied from blood by dietary ingestion as well as from *de novo* synthesis. It is likely that the elevation of hepatic taurine and the decreased production of biosynthesized taurine in obesity induced by HFD are associated with depletion of the blood taurine concentrations. This was confirmed in a recent metabolomic study for HFD-induced mice \[[@B56]\] and obese humans in comparison with age- and sex-matched nonobese subjects \[[@B57]\]. Indeed, Tsuboyama-Kasaoka et al. \[[@B58]\] not only found that blood taurine concentrations were decreased in HFD-induced obese mice, but also that dietary taurine supplementation could reverse the obesity induced by HFD. They proposed a role for taurine as a metabolite able to increase fatty acid oxidation and decrease obesity. In the light of this, the increased provision of fatty acids in obesity may require more taurine to promote fatty acid oxidation. Thus, the obesity in the GHR mutant mice is likely to be a consequence of the low taurine levels, whereas the elevation of hepatic taurine seen in HFD-fed wild-type mice is a compensatory mechanism to overcome the increased supply of dietary triglycerides by promoting *β*-oxidation \[[@B34]\]. These observations indicate that taurine should be a focus of further investigation with respect to the mechanism of the onset and development of obesity.

2.3. Metabolites Related to Choline Metabolism {#sec2.3}
----------------------------------------------

*Choline* is an essential dietary nutrient that is important for integrity of cellular structure, methyl (one-carbon) metabolism, and lipid/cholesterol transport and metabolism \[[@B59], [@B60]\]. In animals, over 95% of the total choline pool in most tissues is used for the synthesis of phosphatidylcholine (PC) via the Kennedy pathway \[[@B61]\]. In HFD-fed obese mice the hepatic and serum PC was increased compared to normal controls \[[@B41]\]. In the mitochondria of liver and kidney, choline can be oxidized to betaine, whose methyl groups are used to synthesize methionine from homocysteine \[[@B62]\]. It was presumed that betaine plays a key role in fatty acid metabolism related to carnitine production \[[@B41], [@B63]\]. Metabolomic analysis revealed depletion of betaine in the liver of HFD-induced obese mice \[[@B41]\] and Zucker rats \[[@B18]\] which may result in a decreased hepatic carnitine level, and eventually lead to decreased *β*-oxidation and increased fatty acid storage. Indeed, a lower hepatic carnitine level was detected by LC(GC)-MS in HFD-fed obese mice \[[@B41]\].

In mammals, choline is derived not only from diet, but also from *de novo* synthesis. During HFD intervention, hepatic one-carbon metabolism and related pathways are altered significantly. For example, higher hepatic choline levels and lower hepatic methionine concentrations were found in an HFD mouse model \[[@B54]\]. It was suggested that the higher hepatic choline levels were used for synthesizing essential amino acids such as methionine and that these alterations would play an important role in the development of insulin resistance and liver steatosis \[[@B54]\].

However, the amount of choline supplied by *de novo* biosynthesis may be not adequate to meet the demand for choline to maintain health \[[@B59]\]. Indeed, feeding animals a methionine- and choline-deficient (MCD) diet can result in fatty liver, which is similar to human nonalcoholic steatohepatitis (NASH), and MCD diet is a frequently used nutritional model of NASH \[[@B64], [@B65]\]. The mechanism of development of hepatic steatosis induced by MCD diet in mice presumably involves an increase of fatty acid uptake and decrease of very low-density lipoprotein (VLDL) secretion, which would promote intrahepatic lipid accumulation \[[@B66]\].

The pathway from dietary PC/choline to *trimethylamine* (TMA) and *trimethylamine N-oxide* (TMAO) has been known since the 1950s \[[@B67]\]. Recently, Wang et al. \[[@B13]\] crucially demonstrated that intestinal microflora are a key element in this pathway and thus in the generation of TMA from dietary choline *in vivo*. The importance of gut microbiota for TMA production from its precursor choline was also demonstrated with germ-free mice experiments \[[@B68]\]. Thus, metabolites such as TMA and TMAO are directly indicative of gut microbiota status. By combining ^1^H NMR spectroscopy and multivariate statistical techniques, Dumas et al. \[[@B12]\] found a significant association between variations in choline metabolism---for example, low plasma PC and high urinary methylamines (dimethylamine, TMA, TMAO)---and genetic predisposition to HFD-induced nonalcoholic fatty liver disease in mice. Based on this, Dumas et al. proposed a diet-induced mechanism of steatosis, triggered by symbiotic microbiota, which mimic choline-deficient diets \[[@B12]\]. Indeed, gut microbiota have been demonstrated to be able to influence the efficiency of harvesting energy from diet and consequently influence susceptibility to obesity \[[@B69]\]. Several metabolomic studies show depletion of serum or urinary TMAO in HFD-induced obese mice or Zucker rats ([Table 1](#tab1){ref-type="table"}), whereas, elevation of TMAO was observed in GHR mutant obese mice \[[@B34]\]. In addition, urinary excretion of microbiota-derived metabolites was found to vary significantly depending on the mouse strain \[[@B12]\], underlining the importance of gut microbiota in nutrient supply.

2.4. Metabolites Related to Amino Acid Metabolism {#sec2.4}
-------------------------------------------------

Amino acids that were shown to display significant obesity-related variations are listed in [Table 1](#tab1){ref-type="table"}. The branched chain amino acids (BCAAs), *leucine*, *isoleucine*, and *valine*, are among the nine essential amino acids for humans. The BCAAs play important roles in protein synthesis \[[@B70]\], improve glucose metabolism and oxidation \[[@B71]\], and regulate leptin secretion from fat and food intake \[[@B72]\]. BCAA supplementation was found to beneficial for patients undergoing chemoembolization to improve postoperative nutritional status \[[@B73]\]. In mouse models, very low blood levels of BCAAs were associated with neuropathology, including the development of epileptic seizures \[[@B74]\]. However, high levels of BCAAs have been reported in obese persons, and fasting concentrations of branched-chain and aromatic amino acids were correlated with obesity and serum insulin levels \[[@B75], [@B76]\]. Based on metabolic profiling of obese versus lean humans and data obtained from rats on different diets, Newgard et al. \[[@B24]\] demonstrated that BCAAs did contribute to obesity-related comorbidities such as insulin resistance and glucose intolerance. Furthermore, a recent study showed that the blood concentration of five branched-chain and aromatic amino acids (isoleucine, leucine, valine, tyrosine, and phenylalanine) could predict the risk of future diabetes \[[@B77]\]. In agreement with this, plasma levels of valine and leucine were 23% and 14% higher, respectively, in overweight/obese male humans compared to the lean controls \[[@B45]\]. In contrast, some previous studies \[[@B78], [@B79]\] failed to demonstrate the elevation of blood BCAA levels in obese patients, but this may have been caused by a different dietary regimen in the obese subjects \[[@B79], [@B80]\]. Similarly, depletion of serum levels of BCAAs was reported in HFD-fed obese mice in other metabolomic studies \[[@B28], [@B56]\]. An HFD with lower protein content \[[@B28]\] may decrease the supply of BCAAs.

On the other hand, obesity may play a role in the regulation of BCAA catabolism. In animals, BCAAs are presumed to be degraded in muscle and adipose tissue rather than in the liver \[[@B81]\], and a recent study indicated that adipose tissue may make a more important contribution to the whole body BCAA metabolism \[[@B82]\]. It was reported that the activities of the mitochondrial branched chain amino acid aminotransferase and branched chain  *α*-ketoacid dehydrogenase enzyme complex, the key enzymes in the catabolic pathway of BCAAs, were depressed in adipose tissue of obese *ob/ob* mice and Zucker rats, leading to increased BCAA levels \[[@B82]\]. Apart from the elevation of BCAAs in plasma, blood C3 and C5 acylcarnitine levels were observed to increase significantly in obesity \[[@B24]\]. In agreement with this, higher levels of propionyl-, butyryl-, and hexanoylcarnitines in obese male humans have been detected by metabolomics analysis \[[@B45]\]. Indeed, C3 acylcarnitines are a byproduct of both isoleucine and valine catabolism, and C5 acylcarnitines are intermediates in mitochondrial isoleucine and leucine catabolism \[[@B24]\]. In addition, elevation of blood pyruvate and alanine levels ([Table 1](#tab1){ref-type="table"})---both metabolites related to BCAA catabolic pathways---could contribute to development of glucose intolerance in obesity \[[@B24]\]. These metabolite changes may imply an overload of BCAA catabolism in obesity, caused by forcing the now expanded circulating BCAA pool to divert away from protein synthesis and into catabolic pathways \[[@B24]\].

A recent metabolomic study reported that both blood *glutamine* and *glycine* were significantly decreased in obese individuals when compared to their lean controls \[[@B83]\], which is consistent with the results of a previous study \[[@B84]\]. Both glutamine and glycine are nonessential amino acids that can be synthesized in the body. Glutamine is the most abundant amino acid in plasma \[[@B83]\], and glutamate, the precursor of glutamine, can be derived from 2-oxoglutarate in the TCA cycle \[[@B85]\]. Glycine can be generated from serine, an amino acid derived from pyruvate. Early experiments with ^15^N-labeled amino acids demonstrated that about 50% of the urinary ammonia is normally derived from the amide nitrogen and 16\~25% from the amino nitrogen of plasma glutamine \[[@B86]\]. It has been reported that oral administration of glycine or glutamine is associated with a significant increase in the rate of urea synthesis, and administration of glycine results in a small increase in glutamine turnover in infants \[[@B87]\]. Thus, glutamine and glycine are important precursors for urea biosynthesis. In addition, as both glutamine and glycine are related to glucose metabolism, the depletion of glutamine or glycine in blood in obesity may lead to the dysfunction of cells \[[@B85]\].

2.5. Creatine Metabolism {#sec2.5}
------------------------

Endogenous *creatinine* is a break-down product of creatine in muscle, which is biosynthesized from arginine and glycine \[[@B88]\]. *In vivo*, creatinine is usually produced at a fairly constant rate proportional to muscle mass, and then filtered from the blood by the kidneys. However, previous studies showed increased urinary excretion of creatinine in obese individuals during a 4-hour or 24-hour period \[[@B89]\]. Similar results were observed in HFD-fed obese mice and obese GHR mutant mice ([Table 1](#tab1){ref-type="table"}). The reason for this may be related to skeletal and cardiac muscle hypertrophy to support and move the increased body mass \[[@B89]\], endogenous biosynthesis pathways, kidney function, or all of these \[[@B34]\].

In kidney, the excretion of creatinine is chiefly determined by glomerular filtration and proximal tubular secretion since virtually no creatinine is reabsorbed in the nephric tubule. Therefore, creatinine levels in blood and urine may be used to calculate the creatinine clearance, which usually reflects renal function in clinic \[[@B90]\]. It was reported that glomerular filtration rate and renal plasma flow exceeded the normal value by 51 and 31%, respectively, in nondiabetic subjects with severe obesity \[[@B91]\]. However, as indicated, obesity is associated with insulin resistance, hypertension, and dyslipidemia \[[@B89]\]. These metabolic abnormalities pose a higher risk for kidney diseases, which decreases creatinine clearance \[[@B92], [@B93]\], as does aging \[[@B94]\], thus caution is required in interpreting changes in creatinine clearance in obesity and diabetes.

3. Discussion {#sec3}
=============

Metabolomics as a tool for determining biochemical profiles has in recent years been increasingly employed for investigating obesity and related diseases. With technological improvements in sensitivity and resolution, especially in multihyphenated NMR and MS, an increasingly large number of metabolites can be reliably detected and identified simultaneously in biofluids and tissue. In addition, integration and correlation of data derived from different biofluids, such as urine, plasma or tissues, and even of other "omics" data, can be achieved through new bioinformatic approaches \[[@B95]\]. These are expected to facilitate the development of metabolic models to understand the alterations of metabolism during obesity and related diseases such as type 2 diabetes. Based on the examples presented in this review, it is evident that metabolomics, especially when integrating multiple detecting techniques or using a multiomics approach, is a useful tool for investigating obesity. The information generated by metabolomic analysis provides us with increased knowledge as to how the metabolic network is perturbed during obesity.

However, dietary influence is a major issue that should be taken into consideration in metabolomics when relating changes in biologically significant metabolites to obesity. It has been reported that the most recent diet can strongly affect the serum profile of mice, particularly with respect to energy metabolism and glucose utilization, despite fasting prior to serum collection \[[@B19]\]. HFD-fed animal models are widely used for studying environmental influences resulting in obesity \[[@B10], [@B96]\]. However, the modified nutrient composition of HFD with a high content of fat (59%, 21% for standard diet) \[[@B28]\] and lower protein availability may instantly change the biofluid profiles such as amino acids, even before obesity occurs, because the levels of many metabolites derive from the balance of *de novo* synthesis, dietary supplement, and urinary excretion. In addition, it was found that the food intake of obese mice induced by HFD was decreased approximately 10% \[[@B41]\]. Therefore, in metabolomic analysis the effect of diet needs to be taken into account to obtain the metabolite alterations related to obesity rather than to diet changes.
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Metabolite changes in obesity.

  Pathway                            Metabolite^a^              Model/sample^b^           Analytical platform   Reference
  ---------------------------------- -------------------------- ------------------------- --------------------- ------------
  Glucose metabolism and TCA cycle   Lactate (+)                HFD rat/urine             ^1^HNMR               \[[@B20]\]
                                                                HFD mouse/serum           ^1^HNMR               \[[@B19]\]
                                                                Zucker rat/liver, blood   ^1^HNMR               \[[@B18]\]
                                                                Zucker rat/urine, blood   ^1^HNMR               \[[@B21]\]
                                                                LDLr mouse/liver          ^1^HNMR               \[[@B22]\]
                                     Lactate (−)                HFD mouse/serum           ^1^HNMR               \[[@B56]\]
                                                                Zucker rat/urine          ^1^HNMR               \[[@B23]\]
                                     Acetate (+)                Zucker rat/ blood         ^1^HNMR               \[[@B18]\]
                                                                Zucker rat/urine          ^1^HNMR               \[[@B21]\]
                                     Acetate (−)                HFD mouse/serum           ^1^HNMR               \[[@B28]\]
                                                                HFD mouse/urine           ^1^HNMR               \[[@B55]\]
                                                                HFD mouse/serum           ^1^HNMR               \[[@B56]\]
                                     Citrate (+)                HFD mouse/serum           ^1^HNMR               \[[@B28]\]
                                                                HFD rat/urine             ^1^HNMR               \[[@B20]\]
                                                                HFD rat/serum             GC-MS                 \[[@B32]\]
                                     Citrate (−)                HFD rat/urine             GC-MS                 \[[@B32]\]
                                                                Zucker rat/urine          ^1^HNMR               \[[@B23]\]
                                                                M391 mouse/urine          ^1^HNMR               \[[@B34]\]
                                     Pyruvate (+)               HFD rat/urine             ^1^HNMR               \[[@B20]\]
                                                                HFD mouse/serum           ^1^HNMR               \[[@B19]\]
                                     Succinate (+)              HFD mouse/serum           ^1^HNMR               \[[@B19]\]
                                                                HFD rat/liver             GC-MS                 \[[@B32]\]
                                     2-Oxoglutarate (−)         M391 mouse/urine          ^1^HNMR               \[[@B34]\]
                                                                                                                
  Lipid metabolism                   Fatty acid (+)             HFD rat/liver, serum      GC-MS                 \[[@B32]\]
                                                                Zucker rat/liver          ^1^HNMR               \[[@B18]\]
                                                                HFD mouse/liver           LC (GC)-MS            \[[@B42]\]
                                                                Human/blood               UPLC-MS               \[[@B46]\]
                                     Taurine (+)                HFD rat/urine             ^1^HNMR               \[[@B20]\]
                                                                HFD mouse/liver           ^1^HNMR, LC-MS        \[[@B54]\]
                                                                HFD mouse/liver           ^1^HNMR               \[[@B55]\]
                                                                HFD mouse/serum           ^1^HNMR               \[[@B19]\]
                                                                HFD mouse/liver           ^1^HNMR               \[[@B34]\]
                                                                Zucker rat/urine          ^1^HNMR               \[[@B23]\]
                                     Taurine (−)                HFD mouse/serum           ^1^HNMR               \[[@B56]\]
                                                                Zucker rat/urine          UPLC-MS               \[[@B53]\]
                                                                M391 mouse/liver, urine   ^1^HNMR               \[[@B34]\]
                                                                Zucker rat/urine          ^1^HNMR               \[[@B21]\]
                                     Carnitine (+)              HFD mouse/serum           LC (GC)-MS            \[[@B42]\]
                                     Carnitine (−)              HFD mouse/liver           LC (GC)-MS            \[[@B42]\]
                                                                Human/blood               UPLC-MS               \[[@B46]\]
                                     PCs (+); lysoPCs (−)       HFD mouse/serum, liver    LC (GC)-MS            \[[@B42]\]
                                                                                                                
  Choline metabolism                 Choline (+)                HFD mouse/liver           ^1^HNMR, LC-MS        \[[@B54]\]
                                                                Zucker rat/blood          ^1^HNMR               \[[@B21]\]
                                                                Zucker rat/urine          ^1^HNMR               \[[@B23]\]
                                     Betaine (+)                HFD rat/urine             ^1^HNMR               \[[@B20]\]
                                     Betaine (−)                HFD mouse/liver           LC (GC)-MS            \[[@B42]\]
                                                                Zucker rat/liver          ^1^HNMR               \[[@B18]\]
                                                                Zucker rat/urine          ^1^HNMR               \[[@B21]\]
                                     TMAO (−)                   HFD mouse/serum           ^1^HNMR               \[[@B28]\]
                                                                HFD mouse/urine           ^1^HNMR               \[[@B55]\]
                                                                HFD mouse/serum           ^1^HNMR               \[[@B56]\]
                                                                Zucker rat/urine          ^1^HNMR               \[[@B21]\]
                                     TMAO (+)                   M391 mouse/urine          ^1^HNMR               \[[@B34]\]
                                     TMA (+)                    M391 mouse/urine          ^1^HNMR               \[[@B34]\]
                                     TMA (−)                    HFD mouse/urine           ^1^HNMR               \[[@B55]\]
                                     Sarcosine (+)              HFD mouse/liver           NMR, LC-MS            \[[@B54]\]
                                     Hippurate (−)              HFD mouse/serum           ^1^HNMR               \[[@B28]\]
                                                                Human/urine               ^1^HNMR               \[[@B97]\]
                                                                                                                
  Amino acid metabolism              BCAA (+)                   Human/blood               UPLC-MS               \[[@B46]\]
                                                                HFD rat/liver             GC-MS                 \[[@B32]\]
                                     BCAA (−)                   HFD mouse/serum           ^1^HNMR               \[[@B28]\]
                                                                HFD mouse/urine           ^1^HNMR               \[[@B55]\]
                                                                HFD mouse/liver           LC (GC)-MS            \[[@B42]\]
                                                                HFD mouse/serum           ^1^HNMR               \[[@B56]\]
                                                                HFD rat/urine             GC-MS                 \[[@B32]\]
                                     Methionine (+)             Zucker rat/liver          ^1^HNMR               \[[@B18]\]
                                     Methionine (−)             HFD mouse/liver           ^1^HNMR, LC-MS        \[[@B54]\]
                                                                HFD mouse/serum           ^1^HNMR               \[[@B56]\]
                                     Glycine (−)                HFD mouse/liver           ^1^HNMR, LC-MS        \[[@B54]\]
                                                                Zucker rat/blood          ^1^HNMR               \[[@B21]\]
                                                                HFD rat/liver,serum       GC-MS                 \[[@B32]\]
                                     Serine (−)                 HFD mouse/liver           ^1^HNMR, LC-MS        \[[@B54]\]
                                     Alanine (+)                HFD mouse/serum           LC (GC)-MS            \[[@B41]\]
                                                                HFD rat/liver,serum       GC-MS                 \[[@B32]\]
                                     Tyrosine (+)               Human/blood               UPLC-MS               \[[@B45]\]
                                                                HFD mouse/serum           LC (GC)-MS            \[[@B41]\]
                                                                HFD rat/urine             GC-MS                 \[[@B32]\]
                                     Tyrosine (−)               HFD rat/liver             GC-MS                 \[[@B32]\]
                                     Lysine (−); Arginine (−)   HFD mouse/serum           ^1^HNMR               \[[@B28]\]
                                     Phenylalanine (−)          HFD mouse/urine           ^1^HNMR               \[[@B55]\]
                                     Glutamate (−)              Zucker rat/blood          ^1^HNMR               \[[@B21]\]
                                                                                                                
  Creatine metabolism                Creatinine (+)             M391 mouse/urine          ^1^HNMR               \[[@B34]\]
                                                                HFD mouse/urine           ^1^HNMR               \[[@B55]\]
                                     Creatine (+)               HFD mouse/serum           ^1^HNMR               \[[@B19]\]
                                                                M391 mouse/urine          ^1^HNMR               \[[@B34]\]
                                                                Zucker rat/urine          ^1^HNMR               \[[@B23]\]
                                     Uric acid (+)              HFD mouse/serum           LC (GC)-MS            \[[@B42]\]

^a^(+) and (--) indicate an increase or decrease in relative metabolite concentration, respectively, when comparing obesity with control.

^b^"Model" denotes the genetic or dietary cause of obesity, "sample" denotes the type of biological sample.

[^1]: Academic Editor: Chiu-Chung Young
